What's hot
View all perspectives
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj
Adela Castro AdelaCastro222
3 months ago
🚨Diagnostic delays are real in axSpA:
-Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA.
-Increases disease burden and productivity losses.
-EMMs can present before articular sx
-Uveitis and IBD associated with longer dx delays.
-Diagnosis has improved since https://t.co/rWMwG7Ewwe
Janet Pope Janetbirdope
3 months ago
#guidelines everywhere
@jeffsparks presents points of interest from #ACR #ILD #recommendations
- a joint venture with American College of Chest Physicians
While simultaneously the EULAR ILD recommendations are being unveiled!
@RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9
Antoni Chan MD (Prof) synovialjoints
3 months ago
A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK
Antoni Chan MD (Prof) synovialjoints
3 months ago
In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7
Dr. John Cush RheumNow
3 months ago
Late-Onset Disease: Different Age, Different Rules?
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/Txvr62UpWZ
Janet Pope Janetbirdope
3 months ago
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Mrinalini Dey DrMiniDey
3 months ago
In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment?
@RheumNow #EULAR2025 #OP0330
David Liew drdavidliew
3 months ago
Some RA-ILD is less of a worry, some is critical. How do we stratify?
Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6.
We need to do this more, so we can go really hard early when we need to.
#EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2
Mrinalini Dey DrMiniDey
3 months ago
🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity:
💶Cost =barrier in 🇳🇱
⛈️Weather =barrier in 🇹🇷
🧑⚕️HCP support =key in 🇫🇷
🏃Active transport & knowledge =enablers in 🇨🇭
Tailored physical activity interventions needed.
@RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7
David Liew drdavidliew
3 months ago
We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs:
- lower inflamm
- higher comorbidities
Doesn’t necessarily map to fibromyalgia dx
Beyond Rx, this is the critical question
CareRA/2000
#EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb
Jiha Lee JihaRheum
3 months ago
Tofacitinib vs biologics in PsA:
📍MI/stroke ✅ similar
📍Serious infection ✅ similar
📍Malignancy ✅ similar
📍VTE ❌ higher vs TNFi (aHR 0.26)
Large US claims study (n=48k)
Abstract POS0296 @RheumNow #EULAR2025
Poster Hall